Supplementary material to article by P. Davila-Seijo et al. "Factors Associated with Receiving Biologics or Classic Systemic Therapy for Moderate-to-Severe Psoriasis: Evidence from the PSONET Registries"

Table SIII. Disease-related variables of patients with psoriasis in both biologic and control group among different registries

| Characteristics of psoriasis | Biologics | | Conventional treatment | |
|--|---------------|------------------|------------------------|-----------------|
| | Patients n | Mean (95% CI) | Patients n | Mean (95% CI) |
| | | | | |
| AMC psoriasis registry, The Netherlands | 189 | 25.1 (23.2-27.1) | NA | NA |
| Australian Psoriasis | 337 | 26.0 (24.5-27.5) | 20 | 27.0 (20.0-34.0 |
| Biobadaderm, Spain | 786 | 25.3 (24.3-26.3) | 629 | 29.8 (28.5-31.1 |
| Clalit Health Service, Israel | 554 | 49.8 (48.6-51.1) | 3,204 | 51.0 (50.5-51.6 |
| Dermbio, Denmark | 901 | 27.2 (26.2-28.2) | 133 | 26.3 (23.7-28.9 |
| PsoBest, Germany | 349 | 28.0 (26.5-29.5) | 1,100 | 29.0 (28.0-30.0 |
| Psocare, Italy | 6,006 | 30.0 (29.6-30.4) | 5,215 | 34.0 (33.5-34.5 |
| Percentage with psoriasis different from pla | aque psoriasi | S | | |
| Australian Psoriasis | 22 | 5.6 (3.3-7.9) | 2 | 6.9 (-2.3-16.1 |
| Biobadaderm, Spain | 41 | 5.2 (3.6-6.7) | 62 | 9.8 (7.5-12.1) |
| Dermbio, Denmark | 109 | 10.1 (8.3-11.9) | 8 | 5.0 (1.6-8.3) |
| PsoBest, Germany | 26 | 6.8 (4.3-9.4) | 107 | 9.1 (7.5-10.8) |
| Psocare, Italy | 829 | 13.4 (12.5–14.2) | 953 | 17.7 (16.7–18.8 |
| Percentage with arthritis | | | | |
| AMC psoriasis registry, The Netherlands | 50 | 27.6 (21.1-34.1) | NA | NA |
| Australian Psoriasis | 190 | 39.8 (35.4-44.2) | 7 | 24.1 (8.6-39.7) |
| Biobadaderm, Spain | 133 | 16.8 (14.2–19.4) | 50 | 7.9 (5.8–10.0) |
| Dermbio, Denmark | 337 | 31.1 (28.4–33.9) | 56 | 34.8 (27.4-42.1 |
| PsoBest, Germany | 150 | 39.5 (34.6-44.4) | 138 | 11.8 (9.9–13.6) |
| Psocare, Italy | 2,170 | 35.1 (33.9–36.2) | 729 | 13.6 (12.7–14.5 |
| Percentage with nail disease | 2/1/0 | 0012 (0015 0012) | , 25 | 1010 (1217 1110 |
| Australian Psoriasis | 71 | 14.9 (11.7-18.1) | 5 | 18.5 (3.9-33.2) |
| Dermbio, Denmark | 115 | 10.6 (8.8–12.5) | 20 | 12.4 (7.3-17.5) |
| PsoBest, Germany | 115 | 64.2 (59.4-69.0) | 20 | 51.0 (48.2-53.9 |
| Psocare, Italy | 2,591 | 41.9 (40.6-43.1) | 1,785 | 33.2 (32.0-34.5 |
| Mean Psoriasis Area and Severity Index | 2,391 | 41.9 (40.0-45.1) | 1,705 | 55.2 (52.0-54.5 |
| AMC psoriasis registry, The Netherlands | 173 | 14.5 (13.5–15.5) | NA | NA |
| Australian Psoriasis | 423 | 30.8 (29.0-32.6) | 11 | 25.5 (17.2-33.7 |
| Biobadaderm, Spain | 613 | 16.5 (15.7–17.3) | 478 | 10.3 (9.7–10.9) |
| | 848 | , , | 478 134 | . , |
| Dermbio, Denmark PsoBest, Germany | 848 370 | 10.8 (10.2-11.4) | 1,140 | 12.4 (10.9–13.8 |
| | | 15.3 (14.3–16.4) | | 14.7 (14.2-15.2 |
| Psocare, Italy | 4,505 | 18.5 (18.2–18.9) | 3,977 | 16.4 (16.1–16.7 |
| Mean body surface area | 167 | 10 1 (15 0 20 4) | | |
| AMC psoriasis registry, The Netherlands | 167 | 18.1 (15.8-20.4) | NA 1 12C | NA |
| PsoBest, Germany | 374 | 26.9 (24.7–29.1) | 1,126 | 24.2 (23.1–25.4 |
| Mean Dermatology Life Quality Index | | | | |
| Australian Psoriasis | 99 | 17.2 (15.9–18.6) | 2 | 19.5 (4.8-34.2) |
| Dermbio, Denmark | 595 | 10.2 (9.6-10.8) | 87 | 12.4 (10.9–13.9 |
| PsoBest, Germany | 370 | 12.5 (11.7–13.2) | 1,146 | 11.0 (10.6–11.4 |

CI: confidence interval; NA: not available; AMC: Academic Medical Center.